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PLO01-01
MUC15 INHIBITS DIMERIZATION OF
EGFR AND PI3K–AKT SIGNALING AND
IS ASSOCIATED WITH AGGRESSIVE
HEPATOCELLULAR CARCINOMAS IN
PATIENTS
Ruo-Yu Wang, Lei Chen, Hai-Yang Chen,
Liang Hu, Liang Li, Jing Zhao, Han-Yong Sun,
Hong-Yang Wang and Wei-Ping Zhou
The Second Military Medical University, China
Introduction: Aberrant expression of MUC15 correlates
with development of colorectal adenocarcinoma, and
MUC15 has been reported to prevent trophoblast inva-
sion of human placenta. However, little is known about
the role of MUC15 in pathogenesis of hepatocellular
carcinoma (HCC).
Method: We analyzed HCC samples and matched,
non-tumor liver tissues (controls) collected from 313
patients who underwent hepatectomy in Shanghai,
China, from January 2006 through September 2009.
Levels of mRNAs and proteins were determined by
immunohistochemical, quantitative reverse transcription
PCR, and immunoblot analyses. Statistical analyses
were used to associate levels of MUC15 with tumor
features and patient outcomes.
Results: Levels of MUC15 mRNA and protein were
reduced in a greater percentage HCC samples than con-
trol tissues. Tumors with reduced levels of MUC15
were more likely to have aggressive characteristics (high
levels of a-fetoprotein, vascular invasion, lack of encap-
sulation, poor differentiation) than those with low lev-
els. Patients whose tumors had reduced levels of
MUC15 had shorter overall survival times (24 months,
vs 46 months for patients with tumors with high levels
of MUC15) and time to disease recurrence. Stable
expression of MUC15 in HCC cell lines (SMMC-7721
and HCC-LM3) reduced their proliferation and inva-
sive features in vitro, and ability to form metastatic
tumors in mice. MUC15 reduced transcription of the
matrix metalloproteinases (MMPs) 2 and 7 increased
expression of tissue inhibitor of metalloproteinase-2
(TIMP2), which required phosphoinositide 3-kinase
(PI3K)–AKT signaling. Physical interaction between
MUC15 and epidermal growth factor receptor (EGFR)
led to its relocation and degradation within early endo-
somes and was required for inactivation of PI3K–AKT
signaling.
Conclusions: Reduced levels of MUC15 in HCCs are
associated with shorter survival times of patients and
reduced time to disease recurrence. Expression of
MUC15 in HCC cells reduces their aggressive behavior
in vitro and in mice, by inducing dimerization of
EGFR and decreasing PI3K signaling via AKT.
PLO 01-02
ALPHA-FOETOPROTEIN SLOPE AND
RADIOLOGICAL PROGRESSION AS
SELECTIVE TOOLS FOR HCC LIVER
RECIPIENTS: AN INTENTION-TO-
TREAT ANALYSIS
Quirino Lai1, Ivo Graziadei2, Gerd Otto3, Massimo
Rossi4, Giuseppe Tsone5, Alfonso W Avolio6 and Jan
Lerut1
1University Hospitals St. Luc, Universite catholique
Louvain, Belgium; 2Medical University Innsbruck,
Austria; 3University of Mainz, Germany; 4University
Sapienza, Italy; 5University Tor Vergata, Italy;
6University Cattolica, Italy
Introduction: Milan criteria are recognized as the best
selection for hepatocellular cancer (HCC) patients listed
for liver transplantation (LT). Several other criteria
have been put forward to better stratify patients, their
results are however controversial. The aim of this study
is to investigate the role of parameters which are avail-
able during the waiting period as potential predictors
of drop-out and post-LT recurrence.
Method: Data from 821 HCC patients listed for LT
during the period July 1987–November 2011 were
obtained from a prospectively collected database of six
collaborating European centers. Median follow-up for
the entire population was 3.7 years (range 1.3–7.2).
One hundred thirteen (13.8%) patients dropped out, 47
(5.7%) due to cancer-related causes.
Results: At multivariate Cox regression analysis, alpha-
foetoprotein (AFP) slope >15 ng/ml/month and mRE-
CIST progression were the unique independent risk fac-
tors for both cancer-related drop out and post-LT
recurrence (p < 0.0001). Patientss with AFP slope
>15 ng/ml/month had a worse 5-year intention-to-treat
(ITT) survival (42.9%) and high recurrence (53.1%)
rates (p < 0.0001). Similar results were observed in
patients with radiological tumor progression (42.8 and
41.3%; p < 0.0001). The presence of both risk factors
allowed to stratify better the patients both in relation
to ITT survival and recurrence rates when compared
with MC. They also allowed to increase the number of
potentially transplantable pats by 8.4%.
Conclusions: AFP increase and radiological progression
allow to improve the selection of HCC patients waiting
for LT. Tumor progression, according to both parame-
ters, significantly increases the risk of drop out on the
waiting list and of post-LT recurrence. Monitoring of
these parameters seems to be better than the initial MC
status defined by imaging; this monitoring should be
used in clinical practice in order to further refine the
selection of potential HCC liver recipients.
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PLO 01-03
A RANDOMIZED CONTROLLED TRIAL
COMPARING EMERGENCY
CHOLECYSTECTOMY FIRST VERSUS
SEQUENTIAL COMMON BILE DUCT
ENDOSCOPIC ASSESSMENT/
CHOLECYSTECTOMY FOR
SUSPECTED GALLSTONE MIGRATION
Pouya Iranmanesh, Beatrice Mugnier-konrad,
Jean-Louis Frossard, Philippe Moral, Pietro Majno,
Thai Nguyen, Thierry Berney, Gilles Mentha and
Christian Toso
University Hospitals of Geneva, Switzerland
Introduction: The management of patients with a clini-
cal diagnosis of gallstone migration into the common
bile duct (CBD) is a matter of debate. Endoscopic
CBD exploration is often performed prior to cholecys-
tectomy, but most stones migrate spontaneously to the
duodenum and many of these explorations are unneces-
sary. The present study explores the opportunity to
perform an emergency cholecystectomy first, with the
aim to decrease the length of stay, the number of
required invasive endoscopic procedures and morbidity.
Method: This randomized controlled trial included
patients with a suspected diagnosis of acute gallstone
migration (right upper quadrant pain, documented gall-
stone and increased liver function tests). Exclusion cri-
teria were radiologically-proven CBD stone and/or
acute pancreatitis, acute cholangitis and medical condi-
tions preventing surgery or informed consent. Patients
were 1:1 randomly assigned to a “control group” with
the standard management of sequential CBD endo-
scopic exploration and cholecystectomy, vs. a “chole-
cystectomy first” group undergoing emergency
cholecystectomy/per-operative cholangiogram first, and
subsequent endoscopic stone extraction when required
(power 90%, alpha 5%). Length of stay was the pri-
mary end-point.
Results: Forty-five patients were included in each arm.
Both groups were similar in terms of demographic
data. Patients in the “cholecystectomy first” group had
a shorter hospital stay (6.95  5.83 vs
9.45  5.25 days, p = 0.040), and underwent fewer
invasive endoscopic procedures (16 vs 59, p < 0.0001).
Conversion to laparotomy was necessary in two “chole-
cystectomy first” and in one control patients
(p = 0.561). Severe complications (Dindo/Clavien grade
III or IV) were seen in one “cholecystectomy first”
(severe pancreatitis) and four control patients (abdomi-
nal abscess, severe pancreatitis, intestinal perforation
and cystic duct bile leakage, p = 0.17); all four control
patients required re-surgery/drainage (4 vs 0,
p = 0.041).
Conclusions: This study shows that patients with a sus-
pected diagnosis of gallstone migration should undergo
a cholecystectomy first, allowing for a shorter hospital
stay, fewer invasive endoscopic procedures and a lower
risk of severe complications.
PLO 01-04
PRE-OPERATIVE MUTATIONAL
ANALYSIS OF FINE NEEDLE
ASPIRATES IS FEASIBLE USING NEXT
GENERATION SEQUENCING: STEPS
TOWARD PERSONALIZED
TREATMENT OF PANCREATIC
CANCER
Vicente Valero III, Tyler Saunders, John Cameron,
Joseph Herman, Ralph Hruban, Christine Iacobuzio-
Donahue and Christopher Wolfgang
Johns Hopkins University School of Medicine, USA
Introduction: A personalized approach to the treatment
of pancreatic cancer that is based on genetic status
depends on tissue for genetic analysis. Fine needle aspi-
ration (FNA) is the most commonly used method for
obtaining tissue prior to surgical resection, or for
patients in whom surgical resection is not indicated.
Potentially limiting factors of FNA include the paucity
of malignant cells within a fibroblast-rich stroma and
tumor heterogeneity. Therefore, we sought to deter-
mine: the ability to confidently detect mutant alleles in
low cellularity samples, the concordance between the
FNA and the primary tumor and the feasibility of iden-
tifying driver mutation in clinical FNAs.
Method: We determined the ability to detect cancer-
specific mutations in a wild-type stromal background in
an in vitro model of Panc1 cells diluted into the fibro-
blast cell line, CAF 35, and the genotypic concordance
between FNAs and their matched resected human ade-
nocarcinoma tissues using next-generation sequencing
by Ion Torrent PGM. Finally, the feasibility of driver
mutation identification via FNA was explored by
sequencing clinical FNA samples.
Results: The limit of confident detection occurred at a
1:25 ratio of malignant to stromal cells for both the
KRAS and TP53 mutant alleles corresponding to a
hypothetical carcinoma with 4% neoplastic cellularity.
The concordance rates between the FNA and tumor
samples ranged from 83% to 100%, although there
was 100% concordance for driver mutations in both
samples. Sequencing of clinical FNAs revealed driver
mutations of KRAS, TP53, SMAD4 and CDKN2A
genes.
Conclusions: This is the first study to prove that confi-
dent genotyping of low cellularity FNA samples is pos-
sible and accurately detects the driver mutations in
primary tumors. Genotyping tumors in the neoadjuvant
setting will enable physicians to offer personalized
treatment paradigms according to chemosensitivity,
actionable mutations, overall survival and outcome
data.
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PLO 02-01
THE RISK FACTORS OF THE
OCCURRENCE OF POSTOPERATIVE
COMPLICATION AFTER
LAPAROSCOPIC DISTAL
PANCREATECTOMY
Ki Byung Song, Song Cheol Kim, Young-Joo Lee,
Kwang-Min Park, Jae Hoon Lee, Jeong Su Nam, Jong
Hee Yoon, Dong Joo Lee and Jung Woo Lee
Asan Medical Center, Ulsan University, Korea
Introduction: We analyzed the risk factors of postoper-
ative complication after laparoscopic distal pancreatec-
tomy (LDP).
Method: Eight hundred consecutive patients who
underwent LDP in the Asan Medical Center between
March 2005 and August 2013 were investigated. Eleven
factors (Age, Sex, BMI, ASA, Operative time, the type
of operation, malignancy, experience of surgeon, tumor
size, resected pancreas size, the type of endo GIA) were
analyzed to determine the risk factors for postoperative
complications.
Results: Of the 800 patients, 678 (84.8%) had benign
or low grade malignant neoplasms and 122 (15.3%)
had malignancies. The most common diagnoses were
intraductal papillary mucinous neoplasm (IPMN) in
163 patients (20.4%). We found that 389 patients
(48.6%) underwent spleen saving LDP (SSLDP) and
110 patients (13.8%) with pancreatic ductal adenocarci-
noma underwent LDP with splenectomy (LDPS). Post-
operative complications occurred in 115 (14.3%)
patients, including 78 (9.8%) with pancreatic fistula
(ISGPF grade B,C) during follow period of
28.2 months. There was no postoperative mortality. A
univariate analysis of the 800 patients with LDP indi-
cated that the risk factor of postoperative complication
included male, BMI ≥24 kg/m2, operative time
≥240 minutes, inexperience surgeon, and LDPS (com-
pared with SSLDP).
Conclusions: LDP is a safe and effective procedure
with an acceptable morbidity. However, male patient,
BMI ≥24 kg/m2, operative time ≥240 minutes, opera-
tion by inexperience surgeon, and LDPS were the risk
factors of the occurrence of postoperative complication
after LDP.
PLO 02-02
A NEW STAGING SYSTEM FOR
INTRAHEPATIC
CHOLANGIOCARCINOMA
Yoshihiro Sakamoto, Akinori Miyata, Junichi Shindoh,
Taku Aoki, Junichi Kaneko, Takeaki Ishizawa,
Kiyoshi Hasegawa, Yasuhiko Sugawara and Norihiro
Kokudo
The University of Tokyo Hospital, Japan
Introduction: The staging system for intrahepatic cho-
langiocarcinoma (ICC) has been established and revised
based on the system for hepatocellular carcinoma
(HCC) in eastern and western countries. AJCC 7th
staging system has recently drastically revised the classi-
fication of T factors, excluding the tumor size and add-
ing the periductal invasion. The discrepancy between
the UICC 7th and Japanese LCSGJ 5th staging systems
might highlight the essential prognostic factors of ICC.
Method: Date base of 110 patients undergoing curative
resection for primary ICC excluding combined ICC
and HCC between 1994 and 2011 in a University Hos-
pital was analyzed to discriminate the predictive factors
for survival referring the two staging systems. All the
patients underwent hepatectomy with (n = 34) or with-
out (n = 76) biliary resection and reconstruction.
Results: There was no surgical mortality and the over-
all 5-year survival rate was 41.2%. The number of
tumors (HR = 2.2), the status of vascular invasion
(HR = 1.9) and the nodal metastasis (HR = 3.3)
proved to be significant prognostic factors by multivari-
ate analysis, while neither the tumor size (cut-off value:
2 or 5 cm), macroscopic appearance (MF vs MF+PI
type), nor biliary invasion (b0-2 vs b3-4) predicted the
survivals of patients. A new simple staging system
excluding the tumor size referring LCSGJ 5th system
was proposed; T1-T3 determined by the number of
tumors and vascular invasion and 4 stages determined
by the combination of T and N factors. This system
more accurately stratified the survivals of patients in
comparison with LCSGJ 5th or UICC 7th.
Conclusions: A new staging system for ICC excluding
the tumor size and biliary invasion might better predict
the prognosis of patients than LCSGJ 5th or UICC
7th. A multi-institutional validation analysis by larger
number of patients would be required in the future to
reveal the validity of the new staging system.
PLO 02-03
A VALIDATED MODEL FOR
PREDICTING OUTCOME AFTER LIVER
TRANSPLANTATION: IMPLICATIONS
ON TRANSPLANTING THE
EXTREMELY SICK
Ido Nachmany1, Igor Dvorchik2, Michael DeVera2,
Paulo Fontes2, Anthony Demetris2, Abhinav Humar2
and James Wallis Marsh2
1Tel Aviv Sourasky Medical Center, Israel; 2University
of Pittsburgh Medical Center, USA
Introduction: Given the organ shortage, there is a need
to optimize outcome after liver transplantation (LT).
The aim was to develop a predictive model for subopti-
mal outcome after liver transplantation. Post-transplant
hospital length of stay >60 days (LOS >60) was consid-
ered an indicator of suboptimal outcome.
Method: Retrospective cohort analysis. LOS was the
main outcome measure. Secondary measures were
patient and graft survival, graft and kidney function,
and cost. The study consisted of 1,060 consecutive pri-
mary LTs. The “Study cohort” (SC) of 643 patients
was used to identify risk factors for poor outcome and
construct a model to identify those with inferior results.
Mean follow-up was 40.5  0.8 months. The second
cohort of 417 patients was used for validation of the
model (“Validation Cohort”- VC). Mean follow-up was
54.8  1.3 months.
Results: In the SC, mean LOS was 27.7 days (range 1–
209). Sixty-five patients (10.1%) had LOS >60 days.
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 68–75
70 Plenary oral
One- and three-year patient/graft survival rates were
81.9%/76.1% and 73.4%/67.4%, respectively. Patient
and graft survival of those with LOS >60 days were
significantly inferior (p < 0.0001) while the transplant
cost was significantly greater (3.42 RU vs 1 RU,
p < 0.0001). In a multivariable analysis, pre-transplant
dialysis (p < 0.001), mechanical ventilation (p < 0.015),
MELD (p < 0.003) and age (p < 0.009) were predictors
of LOS >60 days. The ROC curve was 0.75 (95% CI
[0.70, 0.81]). In the VC, 53 patients (12.7%) were
expected to have adverse outcome by the model. These
patients had longer LOS (48.5  4.5 vs
25.6  1.3 days; p < 0.0001), higher cost (1.53 RU vs
1; p < 0.0001) and inferior patient and graft survival (1
and 3 years survival of 71.7% and 64.2% vs 87.6%
and 79.2%; p < 0.007).
Conclusions: Older patients with advanced MELD
score, in need of mechanical ventilation and dialysis,
are prone to inferior outcome after LT.
PLO 02-04
MORTALITY IN HEPATECTOMY:
MODEL FOR END-STAGE LIVER
DISEASE (MELD) AS A PREDICTOR
FOR DEATH USING THE NATIONAL
SURGICAL QUALITY IMPROVEMENT
PROGRAM (NSQIP)
Samuel Ross, Bindhu Oommen, Myung Kim, Amanda
Walters, Vedra Augenstein, John Martinie, Todd
Heniford, Ryan Swan and David A. Iannitti
Carolinas Medical Center, USA
Introduction: Current literature is mixed on the predic-
tive value of MELD score for mortality in hepatec-
tomy. We hypothesized that MELD will independently
correlate with 30-day mortality in patients undergoing
hepatic resection.
Method: The American College of Surgeons NSQIP
database was queried by for patients who underwent a
hepatic resection. Original MELD, UNOS modification
MELD (uMELD), integrated MELD (iMELD), and
sodium corrected MELD (MELD-Na) were also calcu-
lated. Demographics, comorbidities, operative details,
and patient outcomes were compared using standard
statistical tests and examined by uMELD on a contin-
uum and by stratification (0–9, 10–19, 20–30, 30+).
Mortality was then analyzed using logistic regression
and the MELD types were compared using receiver
operating curves (ROC).
Results: There were 11,933 hepatectomies from 2005 to
2011: 7,519 partial; 2,104 right; 1,210 left; and 1,100 tri-
segmentectomy. Demographics and mean MELD
scores: age 58.7  13.4, BMI 28.0  6.3 kg/m2, MELD
3.4  4.8, uMELD 7.9  2.5, MELD-Na 8.2 + 2.9,
and iMELD 31.2 + 5.0. 51.8% were male and 82.5%
were Caucasian. Mean length of stay was
8.4  22.0 days, and there were 275 deaths (2.4%). 30-
day mortality rates by uMELD strata were: 0–9
(1.8%), 10–19 (6.9%), 20–29 (15.4%), 30+ (25.0%);
and on bivariate analysis all MELD types were associ-
ated with higher mortality (p < 0.001). Using logistic
regression, all meld types were independently associated
with mortality (p < 0.001) and uMELD had the largest
effect size (OR: 1.20, 1.17–1.24). However, iMELD had
the narrowest confidence interval (OR: 1.18, 1.15–1.21)
and largest area under the ROC. Using the ROC and
mortality quartile graphs, new strata for iMELD were
defined and mortality is reported: 0–30 (0.9%), 30–34
(1.8%), 35–40 (5.3%), 40+ (12.4%).
Conclusions: Our study is the largest to date on the
topic and shows that hepatectomy patients with higher
MELD scores have increasing rates of 30-day mortal-
ity. For every point increase in uMELD there is a 20%
increase in mortality risk. Additionally, iMELD has the
best predictive characteristics for mortality when com-
pared to other MELD scores.
PLO 03-01
THE ROLE OF ANTIBIOTIC
TREATMENT (AMOXICILLIN PLUS
CLAVULANIC ACID) AFTER EARLY
LAPAROSCOPIC CHOLECYSTECTOMY
FOR GRADE I-II (MILD AND
MODERATE) ACUTE CALCULOUS
CHOLECYSTITIS: AN OPEN-LABEL,
NON-INFERI
Samuel Ross1, Jean Marc Regimbeau1, David Fuks1,
Karine Pautra2, Francois Mauvais3, Vincent Haccart4,
Simon Msika5 and Muriel Mathonnet6
1Amiens University hospital, France; 2Lariboisiere
hospital, France; 3Beauvais hospital, France; 4Montreuil
sur mer hospital, France; 5Louis mouirier hospital,
France; 6Dupuytren hospital, Francearolinas Medical
Center, USA
Introduction: Grade I-II (mild and moderate) acute cal-
culous cholecystitis (ACC) accounts for 90% of all
cases. After early laparoscopic cholecystectomy, 90%
of these patients have an uncomplicated post-operative
course. Although the pre- and peroperative manage-
ment of ACC has been standardized, there are no data
on the utility of post-operative antibiotic (AB) treat-
ment.
Method: We performed an open-label, non-inferiority,
randomized, controlled trial based on the hypothesis
that the absence of post-operative AB treatment (amox-
icillin plus clavulanic acid) would not be inferior to
administration of the said treatment, as evaluated by
the incidence of post-operative infections 4 weeks after
cholecystectomy for ACC.
Results: After recruitment by 17 centers over a
27-month period, the intention-to-treat (ITT) and per-
protocol (PP) populations comprised 414 and 338
patients, respectively. After adjustment for strata, an
ITT analysis showed that the post-operative infection
rates were 13% in the non-AB group and 14% in the
AB group (absolute difference: 1.13%; 95% confidence
interval (CI), 5.6% to 7.8%). In a PP analysis, the
corresponding rates were 12.7% and 13% (absolute dif-
ference: 1.06%; 95% CI, 5.0% to 6.3%). The absence
of AB treatment was not associated with a significantly
worse outcome (relative to AB treatment). Overall,
60.9% of the biliary samples were pathogen-free. Mor-
tality was nil, the mean length of stay was 5 days and
the readmission rate was 6% in both patient group.
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Conclusions: Antibiotic treatment does not appear to
be useful after early laparoscopic cholecystectomy for
mild or moderate ACC.
PLO 03-02
INTERNATIONAL MULTICENTER
STUDY TO CHARACTERIZE THE
INDIVIDUAL RISK OF MALIGNANCY
IN BRANCH DUCT IPMN AND
PROPOSAL OF NORMOGRAM
Jin-Young Jang1, Sun-Whe Kim1, Song Chul Kim2,
Dong Wook Choi3, Seong Ho Choi3, Jin Seok Heo3,
Hee Chul Yu4, Woo Jung Lee5, Chang Moo Kang5,
Sang Geol Kim6, Sohei SATOI7, Tsutomu Fujii8, Ippei
Matsumoto9, Yasuhiro Shimizu10, Goro Honda11,
Hiroaki Nagano12, Satoshi Hirano13, Seiko Hirono14
and Hiroki Yamaue14
1Seoul National University College of Medicine, Seoul,
Korea; 2Ulsan University College of Medicine, Seoul,
Korea; 3Sungkyunkwan University School of Medicine,
Seoul, Korea; 4Chonbuk National University College of
Medicine, Chonbuk, Korea; 5Yonsei University College
of Medicine, Seoul, Korea; 6Kyungpook National
University College of Medicine, Daegu, Korea; 7Kansai
Medical University, Osaka, Japan; 8Nagoya University
Graduate School of Medicine, Nagoya, Japan; 9Kobe
University, Graduate School of Medicine, Kobe, Japan;
10Aichi Cancer Center Hospital, Nagoya, Japan;
11Tokyo Metropolitan Cancer and Infectious diseases
Center Komagome Hospital, Tokyo, Japan; 12Graduate
School of Medicine, Osaka University, Osaka, Japan;
13Hokkaido University Graduate School of Medicine,
Sapporo, Japan; 14Wakayama Medical University
School of Medicine, Wakayama, Japan
Introduction: Branch duct type Intraductal papillary
mucinous neoplasms (BD-IPMNs) have a diverse path-
ologic spectrum. It is difficult to predict malignancy
preoperatively using imaging or biologic diagnostic
tools. Previous reports on malignancy predictors of
BD-IPMN have used different definition and shown
controversial results on same variables. The purpose of
this study was to elucidate the malignant predictor and
evaluate individual risk for malignancy and finally sug-
gest normogram for malignancy prediction of BD-
IPMN using world largest DB of IPMN by Korea-
Japan collaboration study group.
Method: We retrospectively analysed the clinicopatho-
logical factors of 1,685 surgically proven BD-IPMNs at
15 tertiary hospitals in Korea and Japan. We used
stand DB format and definition for BD-IPMN to
reduce hospital variation. Of these patients, we
excluded the patients with main duct dilatation over
10 mm and inadequate information.
Results: A total of 1,532 patients were finally enrolled in
this analysis. Malignant IPMNs were defined as those
with noninvasive and invasive intraductal papillary
mucinous carcinoma. 596 patients had adenoma, 371
borderline, 218 noninvasive carcinoma, and 347 invasive
carcinoma. Cyst size over 3 cm, main duct diameter,
mural nodule and serum tumor markers (CEA, CA19-9)
were independent factor predicting malignancy in multi-
variate analysis with different estimation power.
Conclusions: We propose malignancy predicting norm-
agram for BD-IPMN using meaningful variables
through logistic regression model. It would be very use-
ful to select optimal treatment method considering indi-
vidual risk of malignancy.
PLO 03-03
SINGLE CENTER EXPERIENCE OF
ABO-INCOMPATIBLE ADULT LIVING
DONOR LIVER TRANSPLANTATION:
200 CASES DURING 5 YEARS
Gi-Won Song, Sun-Gyu Lee, Shin Hwang, Ki-Hun
Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha,
Dong-Hwan Jung and Gil-Chun Park
Asan Medical Center, Ulsan University, Korea
Introduction: The widespread application of ABO-
incompatible (ABOi) adult living donor liver transplan-
tation (ALDLT) has been limited due to poor graft
survival despite of its great potential for donor pool
expansion. However, the promising results under ritux-
imab prophylaxis have been reported recently.
Method: The desensitization protocol consisted of pre-
operative rituximab and plasmapheresis. For initial 20
cases, we employed local infusion therapy which was
eliminated from the protocol in later cases. And sple-
nectomy has been added from August 2012.
Results: From November 2008 to July 2013, 200 cases
of ABOi ALDLT (13.5% of total number of ALDLT)
have been performed in our center. The mean age of
recipient was 52.0  7.4 years. The mean MELD score
was 12.4  5.2. There was the only one (0.5%) in-hos-
pital mortality. The 1-, 3-, 5-year patient survival rate
was 96.0%, 93.0% and 93.0%, respectively and graft
survival rate was 92.6%, 89.6% and 89.6%, respec-
tively. Those were superior to that of ABO-compatible
ALDLT during same period. There were 6 cases
(3.0%) of re-transplantation. The incidence of biliary
stricture was 17.0% during mean 19.0 months follow-
up period. Biopsy-proven antibody-mediated rejection
occurred in one patient but multiple intrahepatic biliary
(m-IHBS) strictures in 14 (7.0%) patients. Among 14
patients with m-IHBS, 2 patients died and 4 patients
underwent re-transplantation. By the univariate analy-
sis for m-IHBS, GRWR >1.4%, and recipient age
>55 years were the significant risk factors. However, we
could not find out statistically significant risk factor in
multivariate analysis.
Conclusions: The survival outcome of ABOi adult
LDLT is excellent under rituximab prophylaxis and
should be considered as a valuable option for the
expansion of living liver donor pool. However, the spe-
cial concern needs to be paid for the development of
m-IHBS and we should try to find out associated risk
factor and preventive measures.
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PLO 03-04
ROLE OF NEOADJUVANT
CHEMOTHERAPY IN HIGH AND LOW
RISK RESECTABLE SYNCHRONOUS
COLORECTAL LIVER METASTASIS; AN
INTERNATIONAL MULTI-CENTRE
DATA ANALYSIS USING
LIVERMETSURVEY
Glenn Bonney1, C Coldham1, D Delvart2, G Kaiser3,
E Barroso4, L Capussotti5, C Laurent6, Rene Adam2
and Darius Mirza1
1University Hospitals Birmingham, United Kingdom;
2APHP Hopital Paul Brousse-Univ Paris-Sud, Centre
Hepato-Biliaire, Paris, France, France; 3Essen
University Hospital, Essen, Germany; 4Centreo Hepato-
bilio-pancreatico E De Transplantacao Do Hospital De
Curry Cabral, Portugal; 5Ospedale Mauriziano
“Umberto I”, Torino, Italy; 6University Segalen
Bordeaux, France
Introduction: Neo-adjuvant chemotherapy is increas-
ingly used in the treatment of colorectal liver metastasis
(CLM). We have previously demonstrated a limited
role of neoadjuvant chemotherapy in resectable syn-
chronous liver-only metastasis. We aim here to analyse
if such chemotherapy regimens may have a role in
“high risk” metastasis.
Method: An analysis, from a multi-centric cohort from
the LiverMetSurvey International Registry, of 1,301
patients, who had undergone curative resections for
synchronous CLM without extrahepatic disease,
between May 2000 and June 2011 was undertaken. A
“high-risk” cohort of patients was identified (Fong
score 3 or greater; n = 591). Patients who received at
least 3 cycles of oxaliplatin- or irinotecan-based chemo-
therapy prior to liver surgery were compared with those
who were treated by surgery alone. Baseline clinic-path-
ological variables were compared. The effect of neo-
adjuvant chemotherapy versus surgery alone on overall
survival (OS) and disease-free survival (DFS) of “high-
risk” were analysed.
Results: Clinicopathological comparison of the groups
revealed N-stage (>N1), number of metastasis (>3),
serum CEA (>5 ng/ml) and no adjuvant chemotherapy
independently predicted poorer OS, while N-stage
(>N1), serum CEA (>5 ng/ml) and no adjuvant chemo-
therapy independently predicted poorer DFS, with no
effect of neo-adjuvant chemotherapy on survival. There
was no difference in OS and DFS for “high-risk”
patients receiving neo-adjuvant chemotherapy versus
surgery alone.
Conclusions: Having previously demonstrated no signif-
icant advantage to neo-adjuvant chemotherapy in
resectable liver-only metastasis, we demonstrate here
that in “high-risk” metastasis (as defined by the Fong
score), there also appears to be no significant advan-
tage to this regimen.
PLO 04-01
RANDOMIZED STUDY ON SINGLE
STAGE LAPARO-ENDOSCOPIC
RENDEZVOUS (INTRAOPERATIVE
ERCP) PROCEDURE VERSUS TWO
STAGE APPROACH (PREOPERATIVE
ERCP FOLLOWED BY LAPAROSCOPIC
CHOLECYSTECTOMY) FOR THE MAN
Manash Sahoo1, Ashish Pattnaik2 and Anil Kumar2
1Associate Professor, India; 2Post Graduate, India
Introduction: The “Rendezvous” technique consists of
laparoscopic cholecystectomy standards with intraoper-
ative cholangiography followed by endoscopic sphinc-
terotomy. The sphincterotome is driven across the
papilla through a guidewire inserted by the transcystic
route. In this study we intended to compare the two
methods in a prospective randomized trial.
Method: From 2005 to 2012, we enrolled 83 patients
with a diagnosis of cholecysto-choledocolithiasis. They
were randomized into two groups. In ‘group-A’ constit-
ing of 41 patients were treated with two stages manage-
ment. First by preoperative ERCP and CBD clearance
and 2nd stage by laparoscopic cholecystectomy. In
‘group-B’, 42 patients were treated with laparoscopic
cholecystectomy and intra-operative cholangiography
and when diagnosis of choledocholithiasis was con-
firmed, patients were undergone one stage management
of by Laparo-endoscopic Rendezvous technique.
Results: In Arm A and B group complete CBD clear-
ance was achieved in 29 and 38 patients respectively.
Failure of the treatment in arm- A was 29% and in
arm- B was 9.5%. In Arm A selective CBD cannulation
achieved in 33 cases (80.5%) and in Arm B in 39 cases
(93%). In Arm A group, post ERCP hyperamylasia
was presented in 9 patients (22%) and severe pancreati-
tis in 5 patients (12%) versus none of the patients (0%)
in Arm B group respectively. Mean post-operative hos-
pital stay in arm A and arm B are 10.9 and 6.8 days
respectively.
Conclusions: One stage laparo-endoscopic rendezvous
approach increases selective cannulation of CBD,
reduces post-ERCP pancreatitis, reduces days of hospi-
tal stay, increases patient’s compliance and prevents
unnecessary intervention to CBD.
PLO 04-02
PROPHYLACTIC OCTREOTIDE FOR
PANCREATODUODENECTOMY: MORE
HARM THAN GOOD?
Matthew McMillan1, John Christein2, Mark Callery3,
Stephen Behrman4, Jeffrey Drebin1, Tara Kent3,
Benjamin Miller1, Russell Lewis1 and Charles Vollmer1
1University of Pennsylvania, USA; 2University of
Alabama at Birmingham Medical Center, USA; 3Beth
Israel Deaconess Medical Center, USA; 4University of
Tennessee Health Science Center, USA
Introduction: The value of prophylactic octreotide in
preventing postoperative pancreatic fistula (POPF) fol-
lowing pancreatoduodenectomy (PD) remains debat-
able worldwide. The accrued evidence regarding
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octreotide predates the advent of the ISGPF classifica-
tion system for POPF, and its efficacy in high risk situ-
ations is unknown. The Fistula Risk Score (FRS)
predicts the risk and impact of clinically-relevant fistu-
las (CR-POPF) and can be a useful tool in assessing
the impact of octreotide in scenarios of risk.
Method: From 2001 to 2013, 1,018 PDs were per-
formed at 4 institutions, with prophylactic administra-
tion of octreotide determined at the surgeon’s
discretion. Outcomes were evaluated using the FRS
and the Postoperative Morbidity Index (PMI) to ana-
lyze the occurrence and burden of POPF across various
risk scenarios.
Results: Octreotide was applied in 391 patients (38.4%)
overall. Without risk adjustment, POPFs occurred more
frequently in those who received octreotide (28.1% vs
21.5%; p = 0.017). Octreotide administration correlated
with higher PMI and increased hospital Duration of
Stay (13.4 vs 10.9 days; p < 0.001). Octreotide signifi-
cantly diminished the incidence of Grade A (biochemi-
cal) POPFs, both overall (7.16% vs 14.51%), and when
there was advanced FRS risk. Conversely, CR-POPF
actually occurred more often when octreotide was used
(21.0% vs 7.0%; p < 0.001). CR-POPF rates for octreo-
tide vs no octreotide across the various FRS risk zones
were: Low Risk – 7.5% vs 5.0%; Moderate Risk –
25.4% vs 10.0% (p < 0.001); High Risk – 70.0% vs
17.5% (p < 0.001). Regression analysis, controlling for
FRS risk, demonstrates that CR-POPF rates correspond
with how often individual surgeons used octreotide.
Conclusions: This large, multi-institutional study of
octreotide, using ISGPF criteria, evaluates POPF devel-
opment across the entire risk spectrum. While octreo-
tide improves biochemical fistula rates, it appears to
offer no benefit in preventing CR-POPF. Furthermore,
it may potentiate CR-POPF development in the pres-
ence of risk factors. This comprehensive analysis sug-
gests that octreotide should not be utilized as a POPF
mitigation strategy.
PLO 04-03
SURGICAL BIO-TEXTURE MODELING:
NEW 3D PRINTING TECHNIQUES
USING MDCT DELIVER TANGIBLE
SURGERY TRAINING FOR LIVER
TRANSPLANTATION AND CANCER
RESECTION
Maki Sugimoto
Kobe University Graduate School of Medicine, Japan
Introduction: Our new technology of Surgical Bio-Tex-
ture Modeling by multi-material 3D printing system
enabled manufacturing patient-specific 3D organ copies
by simultaneous jetting of different types of model
materials. We have used 3D personalized organ models
for surgical simulation and navigation purposes. We
evaluated its benefit for liver transplantation and hepa-
tectomy in seven clinical cases.
Method: Based on DICOM data from MDCT, after
generating its surface polygons using OsiriX applica-
tion, the inkjet 3D printer created life-size copies of the
3D liver, vessels, and abdominal cavity. We programed
a printer to create clear models made from acrylic res-
ins that allowed us to visualize and understand the
liver’s complex internal structures of bile duct and
blood vessels or the exact tumor location. We printed
liver models in part from polyvinyl alcohol to make the
model a realistic stand-in for surgical practice.
Results: Before a liver transplant surgery begins, we
have used 3D replicas of a child’s abdominal cavity
and an adult-sized donor’s graft liver to determine
where and how to best trim. We took a knife to a 3D
donor’s liver replica, the models helped us figure out
where to carve it. So that it would fit into the smaller
space while preserving the organ’s key functions, lead-
ing to a successful living-related liver transplant. For
the liver cancer surgeries, the actual size transparent
liver model with vessels and tumor could be manufac-
tured and be handled. All hepatic cancers were success-
fully resected including multiple liver metastases.
Conclusions: Surgeons usually faced a dilemma before
transplanting a parent’s liver into a child, how exactly
to trim the organ to fit the space in the child’s smaller
cavity while preserving its functions. New 3D printing
techniques delivered tangible and safe surgery training
and could help younger, less experienced surgeons prac-
tice with accurate copies for liver transplantation and
cancer resection surgery.
PLO 04-04
TUMOR ANGIOGENIC ATTRIBUTES
AND THE RECURRENCE OF
HEPATOCELLULAR CARCINOMA IN
LIVER TRANSPLANT RECIPIENTS
Włodzimierz Otto, Maria Krol, Urszula Wilkowojska,
Ewa Wilczek, Wacaw Hoowko, Janusz Sierdzinski and
Marek Krawczyk
The Medical University of Warsaw, Poland
Introduction: Microvascular invasion and poor differ-
entiation of hepatocellular carcinoma are the main pre-
dictors of tumor recurrence after liver transplantation
in cirrhotic patients. It is assumed that tumor angio-
genic capability contribute to the increasing rate of
post-transplant relapse, as well. The aim of study was
to evaluate the expression levels of circulating endothe-
lial progenitor cells, serum VEGF concentration, the
tumor VEGF and VEGFR-2 expression, and the con-
tribution of these factors to the early recurrence of
HCC after liver transplantation.
Method: The study were carried out on 45 cirrhotic
patients that had HCC within Milan criteria and were
transplanted in 2009/2010. None of them had been pre-
treated. The comparative group consisted of 42 cir-
rhotic non-tumor patients undergoing OLTx. The rate
of circulating EPCs defined as CD45dim,34+,133+,309+
was assessed by phenotypic analysis of 2 ml fresh blood
in flow cytometer, and serum VEGF concentration was
measured by enzyme-linked immunoassay (ELISA)
prior the transplantation. Liver and tumor tissue sam-
ples were examined for standard pathologic features, as
well as, for expression of VGEF and VEGFR-2 by
immunohistochemical staining with proper monoclonal
antibodies next to the procedure. Patients were fol-
lowed-up to 3 years for tumor recurrence. The data
were analyzed by statistical tests.
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Results: Tumor recurrent in 6 (13.3%). Microvascular
invasion, the elevation in the rate of circulating EPCs,
and the significant difference in the tumor VEGFR-2
expression were found in all relapsed cases (v2 = 2.7,
p < 0.006). The rate of circulating EPCs correlated with
high expression of VEGFR-2 within the tumor
(r = 0.3, p < 0.03), and with VEGF tumor expression
and VEGF serum concentration (r = 0.2, p = 0.1).
Conclusions: Tumor angiogenic capability contributes
to the increasing rate of post-transplant relapse. Pre-
treatment with anti-angiogenic agent should be consid-
ered under this viewpoint.
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